This time we are talking about new drug delivery system based on doxorubicin designed for treatment of liver cancer:
The company, with a market valuation of only about $70 million and all of 16 employees, is not trying to reinvent the wheel. But by placing a very old cancer drug - the chemotherapy doxorubicin - into a new delivery method and adding heat, Celsion believes it has a recipe for success that can address a large need in cancer.
About 750,000 new cases of liver cancer are diagnosed each year. The World Health Organization has predicted that by 2020 liver cancer will surpass lung as the No. 1 cancer worldwide.
ThermoDox is intended for liver cancer patients not eligible for resection surgery.
Tardugno was not ready to predict multiple billions in annual sales just yet and noted that all, of course, depends on positive data from its pivotal late stage trial.
For sure, billions in sales! Well, why not? I see a positive issue here that we have a novel approach which differs from the crazy modern HTS. I think that the company has good chances for success.
No comments:
Post a Comment